Fig. 1: Participant disposition. | Schizophrenia

Fig. 1: Participant disposition.

From: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials

Fig. 1

aThe safety population included all participants who received ≥1 dose of trial drug. bThe modified intent-to-treat population, used for all efficacy analyses, included all participants randomized who received ≥1 dose of trial drug, had a baseline Positive and Negative Syndrome Scale (PANSS) assessment, and had ≥1 postbaseline PANSS assessment. X/T xanomeline/trospium.

Back to article page